NVO
NOVO NORDISK A S
NYSE: NVO · Bagsvaerd Denmark, G7 · Healthcare
$46.60-0.91 (-1.92%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$34.33 – $60.94
Avg Volume17.1M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$46.60-61.6%
Pipeline
Drug candidates sponsored by NOVO NORDISK A S · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | biphasic insulin aspart | Diabetes+1 more | Completed | 2004-06past | 2 | |
| Phase 4 | repaglinide | Diabetes+1 more | Completed | 2008-01past | 2 | |
| Phase 4 | insulin aspart | Diabetes+3 more | Completed | 2009-10past | 4 | |
| Phase 4 | insulin detemir | Diabetes+3 more | Completed | 2010-08past | 9 | |
| Phase 4 | Insulin-Levemir | Diabetes Type 2 | Completed | 2011-04past | 1 | |
| Phase 4 | liraglutide | Diabetes+3 more | Completed | 2017-06-16past | 7 | |
| Phase 3 | human insulin | Diabetes+2 more | Completed | 2004-01-19past | 2 | |
| Phase 3 | 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) | Menopause+1 more | Completed | 2005-05-04past | 1 | |
| Phase 3 | insulin lispro | Diabetes+1 more | Completed | 2006-05past | 1 | |
| Phase 3 | inhaled human insulin | Diabetes+1 more | Terminated | 2008-05-05past | 1 | |
| Phase 3 | Unnamed | Diabetes+3 more | Completed | 2009-06past | 1 | |
| Phase 3 | insulin degludec/insulin aspart | Diabetes+2 more | Completed | 2010-12-23past | 2 | |
| Phase 3 | vatreptacog alfa (activated) | Congenital Bleeding Disorder+2 more | Completed | 2012-08past | 1 | |
| Phase 3 | turoctocog alfa | Congenital Bleeding Disorder+1 more | Completed | 2016-06-28past | 1 | |
| Phase 3 | Semaglutide 0.5 mg | Diabetes+1 more | Completed | 2019-03-14past | 1 | |
| Phase 3 | insulin degludec/liraglutide | Diabetes+1 more | Completed | 2019-06-14past | 2 | |
| Phase 3 | insulin degludec | Diabetes+2 more | Completed | 2020-11-30past | 5 | |
| Phase 3 | Semaglutide 2.4 mg | Obesity+1 more | Completed | 2023-10-16past | 2 | |
| Phase 3 | Cagrilintide | Obesity+2 more | Active, not recruiting | 2025-01-28past | 2 | |
| Phase 3 | Insulin icodec | Diabetes, Type 2+2 more | Completed | 2025-05-08past | 2 | |
| Phase 3 | Semaglutide | Obesity+2 more | Completed | 2025-05-12past | 5 | |
| Phase 3 | Ziltivekimab | Cardiovascular Risk+1 more | Recruiting | 2026-12-14 | 1 | |
| Phase 3 | Cagrisema | Overweight+1 more | Withdrawn | 2027-11-29 | 1 | |
| Phase 2 | recombinant interleukin-21 | Cancer+1 more | Completed | 2009-01-07past | 1 | |
| Phase 2 | NNC0109-0012 | Inflammation+1 more | Withdrawn | 2015-09past | 1 | |
| Phase 2 | NDec - oral decitabine-tetrahydrouridine | Sickle Cell Disease | Completed | 2025-07-24past | 1 | |
| Phase 2 | NNC0194-0499 | Alcohol-related Liver Disease | Completed | 2025-11-21past | 1 | |
| Phase 1 | Unnamed | Diabetes+2 more | Completed | 2005-09past | 1 | |
| Phase 1 | isophane human insulin | Diabetes+1 more | Completed | 2006-07past | 1 | |
| Phase 1 | NNC126-0083 | Growth Hormone Disorder+1 more | Completed | 2008-01past | 1 | |
| Phase 1 | NNC 0151-0000-0000 | Inflammation+3 more | Completed | 2009-10past | 1 | |
| Phase 1 | NNC 0070-0002-0349 | Metabolism and Nutrition Disorder+1 more | Withdrawn | 2009-12past | 1 | |
| Phase 1 | placebo | Diabetes+2 more | Completed | 2016-02-25past | 1 | |
| Phase 1 | Faster-acting insulin aspart | Diabetes+1 more | Completed | 2016-04-25past | 2 | |
| Phase 1 | Furosemide | Diabetes+1 more | Completed | 2017-06-04past | 1 | |
| Phase 1 | turoctocog alfa pegol | Congenital Bleeding Disorder+1 more | Completed | 2018-10-15past | 1 | |
| Phase 1 | Faster Aspart 200 U/mL | Diabetes Mellitus, Type 1 | Completed | 2019-03-21past | 1 | |
| Phase 1 | NNC0165-1875 | Obesity and Overweight | Completed | 2019-08-13past | 1 | |
| Phase 1 | NNC9204-1706 | Metabolism and Nutrition Disorder+1 more | Completed | 2019-09-05past | 1 | |
| Phase 1 | NNC0174-0833 | Overweight+1 more | Completed | 2021-01-05past | 1 | |
| Phase 1 | NNC0480-0389 | Healthy Volunteers Type 2 Diabetes | Completed | 2021-07-20past | 1 | |
| Phase 1 | Oral semaglutide | Diabetes Mellitus, Type 2 | Completed | 2023-03-03past | 2 | |
| Phase 1 | NNC0519-0130 | Diabetes Mellitus, Type 2 | Completed | 2024-11-27past | 1 | |
| Phase 1 | NNC0487-0111 (formulation D) | Obesity+1 more | Completed | 2025-06-05past | 1 | |
| Phase 1 | UBT251 | Obesity+1 more | Recruiting | 2027-04-07 | 1 | |
| Phase 1 | NNC0662-0419 | Overweight+1 more | Recruiting | 2027-04-08 | 1 | |
| Phase 1 | NNC0705-0002 | Healthy Volunteers+1 more | Not yet recruiting | 2027-08-01 | 1 | |
| N/A | Unnamed | Diabetes+2 more | Completed | 2009-09past | 1 | |
| N/A | biphasic insulin aspart 30 | Diabetes+1 more | Completed | 2010-09past | 4 | |
| N/A | Unnamed | Congenital Bleeding Disorder+5 more | Completed | 2012-02-29past | 1 | |
| N/A | Unnamed | Diabetes+1 more | Completed | 2013-11past | 1 | |
| N/A | somatropin | Genetic Disorder+4 more | Completed | 2016-09-30past | 2 | |
| N/A | IDegLira | Diabetes Mellitus, Type 2 | Completed | 2022-10-26past | 1 | |
| N/A | Ozempic® | Diabetes Mellitus, Type 2 | Completed | 2025-11-25past | 1 | |
| N/A | Unnamed | Haemophilia | Enrolling | 2025-12-19past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2+3 more | Enrolling | 2026-08-03past | 1 | |
| N/A | Unnamed | Haemophilia A | Not yet recruiting | 2026-10-26 | 1 | |
| N/A | Unnamed | Liver Disease | Recruiting | 2027-02-23 | 1 | |
| N/A | Nonacog beta pegol | Haemophilia B | Enrolling | 2027-12-15 | 1 | |
| N/A | Norditropin | Noonan Syndrome | Enrolling | 2028-03-17 | 1 | |
| N/A | Unnamed | Parkinson Disease | Enrolling | 2030-03-11 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for NVO. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.